Dr. Alter Discusses Provenge MOA and Tolerability

Robert S. Alter, MD
Published Online: Friday, Dec 02, 2011

Robert S. Alter, MD, co-chief, Urologic Oncology, John Theurer Cancer Center, discusses the mechanism of action (MOA) and tolerability of the immunotherapy Provenge (sipuleucel-T) in men with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer.

The product of the Provenge vaccine stimulates the immune system by activating t-cells to recognize prostate cancer cells. The vaccine is created from the patient’s own cells, which prevents it from being rejected by the body.

Provenge provides a well-tolerated active therapy. The response varies from patient-to-patient ranging from nominal to prolonged. A survival benefit for Provenge was derived from several controlled trials. The median survival benefit from the vaccine is 25.8 months, compared to 21.7 in control groups.

Robert S. Alter, MD, co-chief, Urologic Oncology, John Theurer Cancer Center, discusses the mechanism of action (MOA) and tolerability of the immunotherapy Provenge (sipuleucel-T) in men with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer.

The product of the Provenge vaccine stimulates the immune system by activating t-cells to recognize prostate cancer cells. The vaccine is created from the patient’s own cells, which prevents it from being rejected by the body.

Provenge provides a well-tolerated active therapy. The response varies from patient-to-patient ranging from nominal to prolonged. A survival benefit for Provenge was derived from several controlled trials. The median survival benefit from the vaccine is 25.8 months, compared to 21.7 in control groups.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Castrate Resistant Prostate Cancer and Advanced MelanomaAug 10, 20162.5
Clinical Vignette Series: 33rd Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 19, 20173.0